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Repulsive guidance molecule A (RGMa) is a potent
inhibitor of neuronal regeneration and a regulator of
cell death, and it plays a role in multiple sclerosis
(MS). In autopsy material from progressive MS pa-
tients, RGMa was found in active and chronic le-
sions, as well as in normal-appearing gray and white
matter, and was expressed by cellular meningeal
infiltrates. Levels of soluble RGMa in the cerebrospi-
nal fluid were decreased in progressive MS patients
successfully treated with intrathecal corticosteroid
triamcinolone acetonide (TCA), showing functional
improvements. In vitro, RGMa monoclonal anti-
bodies (mAbs) reversed RGMa-mediated neurite
outgrowth inhibition and chemorepulsion. In animal
models of CNS damage and MS, RGMa antibody
stimulated regeneration and remyelination of
damaged nerve fibers, accelerated functional recov-
ery, and protected the retinal nerve fiber layer as
measured by clinically relevant optic coherence to-
mography. These data suggest that targeting
RGMa is a promising strategy to improve functional
recovery in MS patients.
INTRODUCTION
Over the last 50 years, inflammatory immune-mediated mecha-
nisms have dominated themultiple sclerosis (MS) field and led to
the development of partially effective immune-modulatory or
immunosuppressive drugs. These drugs work by interfering
with aberrant immune system regulation and function. However,
in the last 15 years, a paradigm shift occurred in MS researchCellattributing permanent disability to axon and neuron degenera-
tion (Trapp and Nave, 2008; Compston and Coles, 2008; Hauser
and Oksenberg, 2006). This resulted in the widely accepted view
that axonal degeneration, often initiated by inflammatory demy-
elination, is the major cause of permanent neurological disability
in MS. In addition to axonal transection and axonal loss
described in postmortem studies, brain and spinal cord atrophy
have been observed in MS patients, estimating the total axon
loss in spinal cord lesions of end-stage MS disease of up to
70% (Trapp and Nave, 2008).
Different mechanisms of axonal degeneration have been dis-
cussed for acute and chronic demyelinating lesions, including
(1) increased vulnerability of demyelinated axons toward toxic
factors of the inflammatory environment (e.g., proteolytic
enzymes, cytokines, free radicals, and oxidative products),
(2) nitric-oxide-mediated axon damage or dysregulation of ion
channels, and (3) glutamate-induced excitotoxicity, damaging
axons and oligodendrocytes (Van der Walt et al., 2010; Mira-
valle and Corboy, 2010). Neurodegeneration in MS is worsened
by factors inhibiting regeneration and remyelination, thereby
preventing any compensatory neurorestorative mechanisms
(Schirmer et al., 2013; McQualter and Bernard, 2007). One
such inhibitory protein with both regeneration-inhibitory and
cell-death-regulating activities is repulsive guidance molecule
A (RGMa), described as a neurite growth inhibitor during devel-
opment of topographic neuronal projections in chick embryos
(Monnier et al., 2002). In a rat spinal cord injury model, RGMa
emerged as an important factor inhibiting neuronal regenera-
tion and functional recovery (Hata et al., 2006; Kyoto et al.,
2007). RGMa is a glycosylphosphatidylinositol-anchored glyco-
protein that exists in membrane-bound and soluble forms, both
of which inhibit neurite growth (Tassew et al., 2012) by binding
to its neuronal receptor, neogenin (Rajagopalan et al., 2004), a
member of the immunoglobulin (Ig) superfamily consisting of
four Ig-like domains, six fibronectin type III domains, aReports 10, 1887–1898, March 24, 2015 ª2015 The Authors 1887
Table 1. Expression of RGMa in Human Autopsied MS Brain
Tissue
Case No.
(Age, Sex) Lesion (No.) Lesion Type
RGMa
Parenchymal Perivascular
1 (53, F) occipital
plaque (3)
chronic active ++ +
NAWM + +
NAGM ++ +
2 (53, F) parietal
plaque (2)
acute ++ +/++
NAWM ++ ++
3 (68, M) parietal
plaque (3)
acute ++ +
NAWM ++ +
NAGM ++ ++
4 (62, M) parietal
plaque (3)
chronic active +/++ +
NAWM ++ +
NAGM ++ ++
5 (47, F) parietal
plaque (3)
chronic active ++ ++
NAWM ++ +/++
NAGM +++ ++
6 (31, F) parietal
plaque (1)
acute ++ ++
RGMa expression was located in parenchymal and axonal, as well as
perivascular, areas.
F, female; M,male; NAWM, normal adjacent white matter; NAGM, normal
adjacent gray matter. +, slightly positive; ++, positive; +++, highly
positive.transmembrane domain, and an intracellular domain (Mueller
et al., 2006).
Pathologically, RGMa has been localized to CNSmyelin, fresh
lesions, and mature scar tissue in humans suffering from trau-
matic brain injury or ischemic stroke (Schwab et al., 2005).
RGMa is also present in amyloid plaques in Alzheimer’s disease
patients (Satoh et al., 2012) and is increased in the substantia ni-
gra of Parkinson’s disease patients (Bossers et al., 2009). In MS
patients, RGMamodulates T cell responses and is expressed by
immature and mature dendritic cells in MS lesions in both brain
and spinal cord (Muramatsu et al., 2011). Moreover, activated
microglial cells express RGMa on their surface, and its downre-
gulation by minocycline results in enhanced axonal growth both
in vitro and in vivo (Kitayama et al., 2011). The RGMa gene was
recently identified as disease-associated gene in MS patients
and rat models of experimental autoimmune encephalomyelitis
(EAE) (Nohra et al., 2010). Neogenin is expressed by CD4+
T cells (Muramatsu et al., 2011) and is strongly upregulated in
a genome-wide microarray analysis of micro-dissected active
cortical lesions in a patient dying from fulminant progressive
MS (Fischer et al., 2013). The RGMa-neogenin interaction may
therefore be deregulated in immune cells and have a dual role
in MS: regulating cell death, thus contributing to neurodegener-
ation, and preventing regeneration of damaged axons.
Our study shows that in progressive MS patients, RGMa is ex-
pressed in active and chronic lesions, in normal-appearing white
and gray matter, and by lymphocytes in perivenular infiltrates.
RGMa neutralization by antibody results in enhanced regenera-
tion, neuroprotection, increased remyelination, or myelin preser-1888 Cell Reports 10, 1887–1898, March 24, 2015 ª2015 The Authorvation in vivo. A decrease of soluble RGMa was observed in the
cerebrospinal fluid (CSF) only in progressive MS patients who
showed an improvement in functional scores after treatment
with intrathecal triamcinolone acetonide (TCA). RGMa, with its
potent regeneration-inhibiting activity and presence in brain and
spinal cord of MS patients, suggests its crucial role inMS-associ-
atedneurodegeneration.TargetingRGMamay therefore stimulate
regeneration and decrease neurodegeneration in MS patients.
RESULTS
RGMa Is Present in Chronic and Active Lesions
of Progressive MS Patients
The etiology of primary and secondary progressive MS patients
is different from relapsing remitting MS patients, as most, if not
all, current therapeutics available for relapsing-remitting MS
(RRMS) patients fail in progressive MS patients. No regenerative
or neuroprotective drug is available to slow down the excessive
neurodegeneration.
Muramatsu et al. recently showed that RGMa is expressed by
immature and mature dendritic cells in the brain and spinal cord
of MS patients (Muramatsu et al., 2011). To confirm and extend
these studies, human autopsymaterial of six progressiveMS pa-
tients was analyzed with RGMa-specific antibodies. The staining
revealed fairly extensive RGMa+ infiltrates in chronic active pla-
ques, in normal-appearing white matter (NAWM) and normal-
appearing gray matter (NAGM) (Table 1; Figure 1A)—the recog-
nized diseased areas in MS. RGMa expression was found in
brain parenchymal and axonal areas, on CD68+ macrophages
and microglial-like cells, and on CD4+ T cells (Figure 1B). In
blood, CD68+ macrophages and CD4+ T cells also expressed
RGMa (H.R. and P.A.C., unpublished data).
Additionally, considerable amounts of soluble RGMa (sRGMa)
were detected in the CSF of progressiveMS patients (Figure 1C).
Progressive MS patients with a pronounced spinal symptom-
atology are often treatedwith an intrathecal (i.t.) retarded-release
crystalline depot corticosteroid called TCA (Abu-Mugheisib
et al., 2011; Mu¨ller, 2009; Lukas et al., 2009; Hoffmann et al.,
2006). In an observational study with 24 progressive MS pa-
tients, a decrease of RGMa was observed in 14 patients after
repeated treatment with anti-inflammatory TCA. Interestingly,
the other progressive MS patients (n = 10) without functional
improvement showed an increase or no change in sRGMa-
CSF levels (data not shown). The 14 TCA-treated MS patients
showing a decrease in sRGMa-CSF levels had decreased
Expanded Disability Status Scale (EDSS) scores (from 5.1 to
4.6 on average; Figure 1D) and increased walking distance
(from 600 to 1100 m on average; Figure 1E). To differentiate
between various forms of sRGMa, we analyzed the CSF samples
using immunodetection on western blots with an RGMa-
selective polyclonal antibody, which detected several RGMa
fragments (C-terminal, N-terminal, cleaved N-terminal, and
uncleaved forms; Figure 1F). Accordingly, i.t. TCA decreased
both the N-terminal and the C-terminal sRGMa fragments (Fig-
ure 1G). This observation is in line with the functional outcome
of these patients: reduced EDSS ratings (Figure 1D) and
improved maximum walking distance determined at baseline
and on each day after TCA administration. To check whethers
Figure 1. RGMa Is Present in Acute andChronic ActiveMSLesions, Perivascular andParenchymal Regions, andCSF andShows aReduction
after TCA Treatment
(A) Brain sections from autopsy material of MS patients were stained against RGMa and show its expression in perivascular regions in MS plaques (upper left,
arrows), in normal-appearing white matter (upper right, arrows), and on axons in normal-appearing gray matter (lower left, arrows). Scale bar, 10 mm.
(B) RGMa (red deposits) co-localizes with CD4+ and CD68+ cells (blue deposits) in an MS plaque. Co-localization was observed in MS plaques (arrows) in
perivascular (upper left) and parenchymal areas (upper right and lower left). Scale bar, 10 mm.
(C) Intrathecal TCA decreased sRGMa levels in CSFmeasured by a sensitive ELISA after TCA application in patients showing functional improvements (F(3, 39) =
5.78; p = 0.002).
(D) Intrathecal TCA treatment resulted in reduced and improved EDSS scores (F(3, 39) = 10.59; p < 0.0001).
(E) Increased walking distance in TCA-treated progressive MS patients (F(3, 39) = 8.67; p = 0.00016).
(F) Immunoblot analysis of CSF samples of TCA-treated progressive MS patients showing the different RGMa fragments (C-terminal, N-terminal, and truncated
N-terminal).
(G) The levels of the potent inhibitory C- and N-terminal sRGMa fragments are significantly reduced by i.t. TCA.
(H) BDNF levels were not altered in CSF after TCA treatment.
*p < 0.05; **p < 0.01; ***p < 0.001; repeated-measures ANOVA. I, baseline before the first TCA administration; II, before the second TCA administration; III, before
the third TCA administration; and IV, after the third TCA administration. NAWM, normal appearing white matter; NAGM, normal appearing gray matter.neurotrophic protein levels changed, we investigated the
amount of brain-derived neurotrophic factor (BDNF). However,
we were not able to detect any significant alterations of this pro-
tein during the TCA-treatment period (Figure 1H).
5F9 Monoclonal Antibody Inhibits Binding of hRGMa to
Its Receptors and Neutralizes Repulsive Activity
A rat anti-RGMaantibody r5F9wasgeneratedby immunizing rats
with soluble humanRGMa (hRGMa) andselectedbasedonability
to inhibit interaction of hRGMa with neogenin and bone morpho-Cellgenetic proteins (BMP). In immunoblots, r5F9 detected most
prominently bandswithmolecular weight of 33 kDa, correspond-
ing to the N-terminal fragment of hRGMa (Figures S1A and S1B).
A humanized form of 5F9 (h5F9), with the same variable domain
as r5F9, bound specifically to recombinant hRGMaandcynomol-
gus monkey RGMa and cross-reacted with rat RGMa (rRGMa)
with the binding affinities (KD) 3, 2, and 10 nM, respectively (Fig-
ure S1C). The h5F9 antibody also bound to RGMa expressed
by SH-SY5Y neuroblastoma cells (Figure S1D) The antibody
blocked the interaction of full-length hRGMa or of an N-terminalReports 10, 1887–1898, March 24, 2015 ª2015 The Authors 1889
Figure 2. Anti-RGMa Antibody Neutralizes Repulsive Activity of hRGMa In Vitro by Changing Localization of Neogenin in the Membrane
(A) Increasing doses of rat 5F9 (r5F9) neutralize the repulsive and inhibitory activity of recombinant human RGMa fragment (47–168) in neurite growth assays with
human NTera teratocarcinoma cells stained with phalloidin probe. Scale bar, 200 mm.
(B) Dose-dependent neutralization of repulsive activity of hRGMa fragment by r5F9 in NTera neurite growth assays. Neurite outgrowth index wasmeasured using
Image Pro, measuring both neurite length and neurite density. The experiment was repeated three times with the same observation. *p < 0.05; **p < 0.01; ***p <
0.001; one-way ANOVA, Bonferroni multiple comparison test. Error bars represent mean ± SEM.
(C) The anti-RGMa mAb 5F9 neutralizes the chemorepulsive activity of hRGMa in a chemotaxis assay in which the neuroblastoma cells SH-SY5Y migrate via a
membrane into the lower chamber within 24 hr and made visible with a phalloidin-488 probe. Scale bar, 100 mm.
(D) Quantification of the area of migrated SH-SY5Y cells. EC50 of 23 nM for chemorepulsive effect. The experiment was repeated five times in duplicates and
showed similar results. *p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA, Bonferroni multiple comparison test. Error bars represent mean ± SEM.
(E) The anti-RGMa antibody r5F9 inactivates neogenin by inducing its transfer out of lipid rafts by injecting r5F9 into the tectum of chick embryos. In control-
antibody-injected chick embryos, neogenin is mostly localized to the flotillin-positive fractions 2 and 3, whereas in r5F9-injected embryos, most of the neogenin is
no longer present in flotillin-positive fractions 2 and 3 and is localized in fractions 4 and 5.RGMa fragment (47–168) with its receptor, neogenin, with an half
maximum inhibitory concentration (IC50) of 5 nM (0.7 mg/ml)
(Figure S1E) and with its coreceptor, BMP-4, with an IC50 of
4 nM (data not shown). This antibody was also able to inhibit
interaction of hRGMa with BMP-2 and -6 with an IC50 of 3 nM
and 7 nM, respectively (data not shown).
To show this effect in a biological setting, the N-terminal frag-
ment of RGMa (47–168) was coated on a laminin substrate and
the human neuronal cell line NTera 2 was plated on top. After
24 hr, the hRGMa showed a strong neurite-repulsive activity
that could be neutralized in a dose-dependent fashion by appli-
cation of the anti-RGMa antibody r5F9 to the cell culture
medium, and complete neutralization was observed at a con-
centration of 10 mg/ml (Figure 2A). This observation was statisti-
cally confirmed by measuring the neurite outgrowth index
(Figure 2B).
As RGMa possesses another neurite growth inhibitory domain
in the C-terminal region (Tassew et al., 2012; Itokazu et al., 2012),
we then investigated whether 5F9 is able to neutralize full-length1890 Cell Reports 10, 1887–1898, March 24, 2015 ª2015 The Author(fl) hRGMa. We addressed this question by using human
SH-SY5Y neuroblastoma cells, which respond sensitively to
increasing doses of fl hRGMa and to the N-terminal hRGMa frag-
ment. In stripe assays, differentiated SH-SY5Y cells were grown
on coverslips coated with fl RGMa in stripes alternating with
collagen stripes. The cells prefer to grow on collagen stripes,
whereas anti-RGMa treatment reverses this effect (Figures S2A
and S2B). The strong repulsion of migrating SH-SY5Y cells by
the RGMa lanes was dose-dependently reduced by the RGMa
monoclonal antibody (mAb) 5F9 (Figure S2C).
In chemotaxis assays with two chambers, the presence of
10 mg/ml fl hRGMa in the lower chamber strongly inhibitedmigra-
tion of SH-SY5Y cells from the upper chamber through themem-
brane into the lower chamber (Figure 2C). The 5F9 RGMa
antibody neutralized the repulsive activity of fl hRGMa on SH-
SY5Y chemotactic migration dose dependently, with a half
maximum effective concentration (EC50) of 23 nM, whereas the
control antibody did not show any neutralizing activity (Fig-
ure 2D). These results clearly show that 5F9 was able tos
neutralize not only the inhibitory N-terminal fragment but also the
fl hRGMa.
We recently reported that interfering with the cis RGMa-neo-
genin interaction in the same membrane (using an Fc-coupled
fragment of the extracellular domain of neogenin) resulted in a
shift of neogenin out of lipid raft fractions (Tassew et al., 2014).
We were interested whether the RGMa antibody is also able to
induce this shift in the previously used chick embryo system.
By comparing the control with the anti-RGMa antibody, it was
indeed possible to observe a shift from the original density frac-
tions, showing that neogenin is in a lipid density fraction between
flotillin and transferrin receptor (Figure 2E), with flotillin being a
marker for low-density raft fractions and transferrin for high-den-
sity membrane fractions (Allen et al., 2007). Transfer of neogenin
out of lipid rafts inactivated the receptor, thereby explaining the
complete neutralization of fl hRGMa by r5F9.
5F9 Antibody Has Regenerative and Neuroprotective
Activities in the Rat ONC Model
In the optic nerve crush (ONC) model, the left optic nerve of living
rats was compressed for approximately 10 s, 2–3mmbehind the
eye. A minimally invasive ONC method was used from the ante-
rior part of the eye, thereby avoiding extensive surgery and
reducing surgery-related stress to the animals. This resulted in
the formation of an impenetrable lesion (400–600 mm in width)
that could so far not be crossed by regenerating fibers (Berry
et al., 2008). Within 4–6 weeks after nerve crush, more than
80% of the retinal ganglion cells, whose axons form the retinal fi-
ber layer and the optic nerve, died (Berkelaar et al., 1994; Nagata
et al., 2009). As reported, RGMawas detected at the crush site in
a time window of 6 hr to 21 days after crush injury (Schnichels
et al., 2011), and its neutralization is expected to stimulate regen-
eration of optic nerve fibers beyond the crush site. In a first set of
experiments, antibodies were given locally, which resulted in
extensive regenerative growth of injured optic nerve fibers (Fig-
ure S3). Based on published data that ONC results in massive
breakdown of blood vessels running through the optic nerve
(Frank and Wolburg, 1996), we decided to test our anti-RGMa
antibodies in the ONC model after systemic intravenous (i.v.)
application. After systemic application of the RGMamAb (human
and rat 5F9), but not the control mAb p21 (2 mg/kg, i.v., once per
week, or two doses, 2 mg/kg at day 0 and 10 mg/kg at day 21,
i.v.), massive regenerative axon growth was observed beyond
the crush site (Figures 3A and 3B), with the longest fibers found
more than 1.5 mm distal to the crush site. An anti-GAP-43 anti-
body was used to visualize the regenerating fibers. At all dis-
tances measured, either form of the 5F9 mAbs was significantly
more potent than the vehicle control (Figure 3C). In the next set of
experiments, different doses of the 5F9 antibody were tested af-
ter ONC. Significant regenerative axon growth was measured in
the optic nerve after once-per-week systemic i.v. application of
5F9 (0.3 mg/kg, 1 mg/kg, and 3 mg/kg), with increased numbers
of regenerating GAP-43+ fibers found at the higher doses (Fig-
ure 3D). When antibody treatment was started 1 week after
ONC, two different doses of h5F9 (1 and 10 mg/kg, i.v., once
per week) significantly increased axon regeneration beyond the
lesion compared with vehicle- and control-antibody-treated an-
imals (Figure 3E). To answer the question whether RGMa mAbsCellcould be detected at the crush site after systemic i.v. application,
humanized anti-RGMa antibodies were used to allow specific
detection in rat tissue with a selective anti-human IgG secondary
antibody, showing no background in rat tissues. This anti-human
IgG antibody detected the h5F9mAb at the crush site (Figure 3F,
right panel) but detected neither the rat 5F9 nor the rat control
mAb p21 (Figure 3F, left panel).
To answer the question whether RGMa antibody treatment re-
sults in enhanced remyelination, cryostat sections of crushed
optic nerves were stained with the myelin marker myelin basic
protein (MBP) (Figure 3G). In themouse cuprizone demyelination
and remyelination model, MBP had been described as an early
marker for remyelination (Skripuletz et al., 2008; Lindner et al.,
2009). Anti-MBP staining of the crushed optic nerves revealed
a significant increase of the MBP+ area in rats treated with sys-
temic 5F9 antibody (30%) compared to control-antibody-
treated rats (10%) and suggests that 5F9 is accelerating the
process of remyelination (Figure 3H). We also observed strong
remyelination and axon regeneration with local application of
the antibody. The antibody was given locally in the ONC model,
embedded in gel foam at a total amount of 200 mg/rat. An anti-
GAP-43 antibody was used to visualize the regenerating fibers
(Figure S3), which were quantified at different distances from
the optic nerve lesion (Figure 3I).
RGMa mAb Protects the RNLF after ONC
In MS patients, degeneration of the retinal nerve fiber layer
(RNFL) is commonly observed after optic neuritis attacks, and
a single attack can reduce RNFL thickness by 40% (Frohman
et al., 2008a, 2008b; Petzold et al., 2010; Sakai et al., 2011). In
the ONC model, up to 80% of retinal ganglion cells die, resulting
in a decrease of RNFL of 80% in this model (Berkelaar et al.,
1994; Nagata et al., 2009). After seeing these published effects
on RNFL and the positive results on the optic nerve in our hands,
we were interested in determining whether the anti-RGMa anti-
body could prevent the extensive retinal axon loss and the
massive increase in RNFL degeneration after ONC. Rat retinae
were isolated, explanted, and stained using a neuronal marker
for b3-tubulin or neurofilament SMI-31 allowing quantification
of neurites and retinal neurons (Figure 4A). In comparison with
the control antibody (p21) or vehicle, only systemic 5F9 reduced
degeneration of the RNFL in a dose-dependent and highly signif-
icant manner (Figure 4B). In vehicle- or p21-antibody-treated
rats, 70%–75% of the retinal fibers were lost, whereas at the
highest dose of 5F9 (3 mg/kg), loss of retinal fibers was only
25% (Figure 4B). This effect was also observed when the start
of antibody treatment was delayed for 1 week after ONC, where
loss of retinal fibers in rats treated with 10 mg/kg 5F9 was
reduced to 30% whereas control mAb and vehicle-treated rats
showed a loss of 78% of retinal fibers (Figure 4C). To confirm
these results with another method, we used optical coherence
tomography (OCT) to follow RNFL degeneration in living rats af-
ter ONC injury (Figure 4D). Measurements were done 1 week,
5 weeks, and 7 weeks after ONC. As shown in Figure 4E, h5F9
given systemically (10 mg/kg, once per week, i.v.), induced sig-
nificant protection of the RNFL at 5 and 7 weeks post-crush
injury, confirming the results from end-stage immunohistochem-
istry using explanted retinae.Reports 10, 1887–1898, March 24, 2015 ª2015 The Authors 1891
Figure 3. Anti-RGMa Antibodies Promote Regeneration and Remyelination in the Rat Model ONC Injury
(A) Systemic application of 5F9 (2 mg/kg at day 0 and 10 mg/kg at day 21, i.v.) induces massive regenerative axon growth beyond the crush site, visualized by
GAP43 staining, with the longest fibers found more than 1.5 mm distal to it. Scale bar, 300 mm.
(B) Magnification of sections from (A). Scale bar, 100 mm.
(C) Quantification of regenerating fibers was counted in rats treated systemically with r5F9 or h5F9 in comparison to control antibody p21 (mean ±SEM). *p < 0.05;
**p < 0.01; ***p < 0.001; one-way ANOVA, Newman-Keuls multiple comparison test.
(D) Three different doses of 5F9 significantly increased the number of regenerating fibers 500–1,000 mmbeyond the crush site (mean ± SEM). *p < 0.05; **p < 0.01;
***p < 0.001; one way ANOVA, Bonferroni multiple comparison test.
(E) Two different doses of 5F9 significantly increased the number of regenerating fibers 0–500 mmbeyond the crush site evenwith a 1-week treatment delay (mean
± SEM). *p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA, Bonferroni multiple comparison test.
(F) A humanized anti-RGMa antibody can be detected at the crush side (right panels), whereas no tissue background staining was observed in the case of the
antibodies obtained from rats (left panels). Scale bar, 100 mm.
(G) Immunohistochemical staining for MBP (green) of optic nerves revealed that 5F9 antibody increases the myelinated area around the ONC site. Scale bar,
300 mm. Animals were sacrificed after 5 weeks.
(H)QuantificationofMBPstainingat thecrushside. Theexperimentwas repeated three timeswith the sameobservation (mean±SEM). ***p<0.001, unpaired t test.
(I) Local application of r5F9 (200 mg/rat) on the crushed optic nerve led to a significant increase in number of regenerated axons. The experiment was repeated two
times with same outcome (mean ± SEM). *p < 0.05; one-way ANOVA, Bonferroni multiple comparison testSystemic 5F9 treatment also resulted in sprouting of intrareti-
nal neurons in the injured eye (Figures 4 and S4). The number of
sprouting retinal neurons was significantly increased in rats
treated with the anti-RGMa antibody 5F9 (Figures S4A–S4C) in
comparison to rats treated with p21 mAb. In explanted retinae,
increased sprouting of retinal neurons by 5F9 was only observed
in the eye with a crushed optic nerve and not in the healthy con-
trol eye with a normal, non-crushed optic nerve (Figure S4D).
Additionally, cell death in isolated whole-mount retinae was
investigated with propidium iodide staining (Figure 4G). A1892 Cell Reports 10, 1887–1898, March 24, 2015 ª2015 The Authordetailed analysis revealed a significant reduction of cell death
in the retinae of animals treated with an anti-RGMa antibody
compared with vehicle and antibody controls (Figure 4H). These
results demonstrate a very strong neuroprotective effect of anti-
RGMa treatment.
RGMa mAbs Are Active in Targeted EAE Models
Most common rodent EAE models are inflammation driven and
suboptimal to study neural recovery and regeneration mecha-
nisms. However, Kerschensteiner et al. established a focal EAEs
Figure 4. Anti-RGMa Antibodies Protect the RNFL after ONC Injury
(A) Systemic anti-RGMa treatment of rats with crushed optic nerve protects the RNFL, and many fibers are visible converging on the optic nerve head. Scale bar,
500 mm.
(B) Dose-dependent effects of retinal fiber protection in rats treated with three different doses of r5F9 (mean ± SEM). *p < 0.05; **p < 0.01; ***p < 0.001; one-way
ANOVA, Bonferroni multiple comparison test. n = 8 rats/group. The experiment was repeated more than five times with similar outcomes.
(C) Systemic treatment started 1 week after ONC still resulted in a dose-dependent protective effect by anti-RGMa 5F9. Animals were treated once per week for
5 weeks (mean ± SEM). *p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA, Bonferroni multiple comparison test. n = 8 rats/group.
(D) Imaging of RNFL with a spectral domain OCT device (Thorlabs) to measure RNFL thickness in a region close to the optic nerve head (ONH). Asterisk de-
marcates the optic nerve head region. Scale bar, 100 mm. Arrows mark thickness of the RNFL.
(E) Systemic treatment with anti-RGMa 5F9mAb (10mg/kg, i.v., once per week, started 1 week after ONC) protects the RNFL and slows down significantly RNFL
degeneration after ONC (n = 10 per group). Two-way ANOVA, Bonferroni multiple comparison test. Results are depicted as mean ± SEM.
(F) Quantification of sprouting intraretinal neurons after anti-RGMa antibody treatment. Sprouting was investigated in four independent experiments. *p < 0.05;
**p < 0.01; ***p < 0.001; one-way ANOVA, Bonferroni multiple comparison test. n = 8 rats/group. Results are depicted as mean ± SEM.
(G) Representative images of whole-mount retinae stained with PI showing increased cell survival after treatment with r5F9. Scale bar, 500 mm.
(H) Quantification of PI staining in the retinal whole mount. The experiment was repeated three times with six to ten whole retinae per group. *p < 0.05; **p < 0.01;
***p < 0.001; one-way ANOVA, Bonferroni multiple comparison test. Results are depicted as mean ± SEM.model to test neural regeneration capacities of drug candidates
(Kerschensteiner et al., 2004a). Therefore, it was well suited for
our approach with the RGMa mAbs. In this model, local injection
of tumor necrosis factor a (TNF-a) and interferon-g (IFN-g) into
the spinal cord of myelin oligodendrocyte glycoprotein (MOG)-
sensitized Lewis rats induces an inflammatory lesion character-
ized by infiltrating immune cells, activation of microglial cells and
macrophages, demyelination, axon degeneration, local tissue
destruction, and glial scar formation (Figure 5A). As a conse-
quence, hindlimb locomotor activity is impaired (Kerschen-
steiner et al., 2004a). We developed a more severe variant of
this model by increasing the amount of TNF-a and MOG. TheCellfocal lesion is characterized by a massive glial scar and a region
of Wallerian axon degeneration, extending over two to three spi-
nal segments. A more detailed analysis revealed a strong accu-
mulation of ED1+ cells in the glial scar, massive demyelination,
and perilesional RGMa accumulation (Figure 5B). Kerschen-
steiner et al. observed a functional recovery from EAE score of
2.5 to 1.0 within 4 weeks, whereas in our more severe model,
the recovery period was extended by 1–2 weeks longer (data
not shown). A similar maximum score of 2.5 was observed,
which is characterized by a strong hemiparesis of the hindlimbs
and gait instabilities. We used this more severe model to test our
anti-RGMa mAbs by injecting systemically once a week. AsReports 10, 1887–1898, March 24, 2015 ª2015 The Authors 1893
Figure 5. The Anti-RGMa mAb Promotes Regeneration, Remyelination, and Functional Recovery in a Rat Targeted Spinal EAE Model
(A) Spinal injection of inflammatory cytokines at Th8 in MOG-sensitized Lewis rats induced a large lesion and glial scar often extending over one to three spinal
segments. An enlarged area of Wallerian degeneration is also visible. Scale bar, 500 mm.
(B) Immunohistochemistry of inflammatory side shows accumulation of ED1-positivemacrophages (left), massive demyelinationmarked by loss of Luxol fast blue
staining (middle), and increased perilesional anti-RGMa staining (right). Scale bar, 200 mm.
(C) Anti-RGMa 5F9 (i.v., once per week) accelerated functional recovery in a dose-dependent manner in the severe spinal targeted EAE model, and animals
reached a score of 0.5, 22 days after cytokine injection (day 0). Usually, n = 8 rats were used per group. *p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA,
Bonferroni multiple comparison test. The experiment was repeated three times. Results are depicted as mean ± SEM.
(D) Analysis of serial longitudinal cryostat sections to measure the MBP-, CD68- and GAP-43-positive area. 5F9 increased the MBP- and the GAP43 area but
decreased the inflammatory CD68-positive area (mean ± SEM). *p < 0.05; **p < 0.01; ***p < 0.001; one-way ANOVA, Newman-Keuls multiple comparison test.
(E) In a related, rat targeted optic nerve inflammatory model, anti-RGMa antibody (right image), but not the human control antibody (hIgG), was detected at the
inflammatory CD68-positive lesion site. Scale bar, 100 mm.
(F) Rats treated systemically with different doses of h5F9 antibody showed increased growth of GAP-43-positive regenerating fibers into the inflammatory CD68-
positive lesion. Scale bar, 200 mm.
(G) Quantification of regenerative growth of fibers within the CD68+ lesion with different doses of h5F9 (i.v., once per week) (mean ± SEM). *p < 0.05; **p < 0.01;
***p < 0.001; one-way ANOVA, Tukey multiple comparison test.
(H) Anti-RGMa treatment leads to remyelination within the inflamed areas in the targeted EAE model.expected, improved functional recovery was observed in a dose-
dependent manner. This effect started just after two anti-RGMa
injections by a decrease in the EAE scores at 18–20 days post-
cytokine application. The control groups treated with mAb p21
and vehicle, in contrast, did not show any significant improve-
ment in functional scores (Figure 5C) within this time period.
For detailed immunohistochemical analysis, we used serial, lon-
gitudinal spinal cord sections of animals treated with h5F9 and
human isotype control antibody. At the end of the experiments,1894 Cell Reports 10, 1887–1898, March 24, 2015 ª2015 The Authorcryostat sections were prepared for immunohistochemistry
and stained for MBP, CD68, and GAP-43. In comparison with
the human immunoglobulin G (hIgG) control mAb, the RGMa
h5F9 antibody increased significantly the MBP+ and the
GAP-43+ area and decreased the CD68+ lesion area, a marker
for activated macrophages and microglia cells (Figure 5D).
To better recapitulate the optic neuritis commonly observed
in MS patients, the focal spinal EAE model was adapted
to the optic nerve. Using the same protocol of MOGs
sensitization, we were able to induce a single unilateral inflam-
matory lesion of various sizes in the rat optic nerve. Within the
inflammatory lesion, we observed extensive demyelination and
degeneration of optic nerve axons (Wallerian degeneration),
axonal transection, and strong accumulation of CD68+ im-
mune reactivity.
In this inflammatory model, we were able to detect significant
amounts of the humanized 5F9 antibody, but not the human con-
trol antibody, at the inflammatory optic nerve lesion (Figure 5E).
We also found that the CD68+ cells of the inflammatory lesion ex-
pressed large quantities of RGMa (data not shown), confirming
previous results (Kitayama et al., 2011). In 5F9-treated rats, the
number of regenerating fibers and the regenerative GAP-43+
area present within the inflammatory CD68+ lesion was strongly
increased compared to rats treated with an hIgG control anti-
body (Figures 5F and S5). This increase in the amount of regen-
erative axon growth into the inflammatory area was observed at
three different systemic RGMa mAb concentrations (Figure 5G).
Within the lesion area, the MBP staining revealed extensive and
strong staining in RGMa-mAb-treated animals, but not in con-
trol-antibody-treated rats, suggesting an effect on remyelination
(Figure 5H).
DISCUSSION
Most treatments for MS follow an anti-inflammatory or immune
modulatory approach whereby they miss out on an important
aspect of the disease: the neurodegeneration. With our newly
developed antibody approach against RGMa, we try to target
the disease via a different angle and focus on neuroprotection
and neural regeneration. Since the anti-human RGMa antibody
5F9 shows cross-reactivity with rat RGMa, this enabled testing
the antibody in rat disease models. Since most conventional
MS models focus on inflammatory aspects and RGMa inhibition
would likely result in neural regeneration and/or neuroprotection,
we used different strategies to evaluate the potential of RGMa
antibodies. These animal models included (1) analysis of protec-
tion of retinal ganglion cells and the RNFL, analysis of regenera-
tive growth of retinal ganglion cell axons, and myelin preserva-
tion in ONC models; (2) evaluation of functional recovery,
preservation or formation of myelin, and lesion development in
targeted spinal EAE models; and (3) evaluation of fiber regener-
ation in an inflammatory lesion in an optic-neuritis-like targeted
optic nerve EAE model. Systemic treatment with the potent
RGMa-neutralizing antibody 5F9 stimulated regeneration of
axons in all these models: ONC injury and focal spinal and optic
nerve EAE. 5F9 enabled regenerating axons to grow into an in-
flammatory lesion and conferred significant and strong protec-
tion of retinal ganglion cells in the ONCmodel, visible as a strong
preservation of the RNFL. In addition to enhanced regeneration
and increased neuroprotection, the RGMa antibody also signifi-
cantly increased area of MBP+ staining in crushed optic nerves,
which can be regarded as a first indication of enhanced remyeli-
nation (Lindner et al., 2009; Skripuletz et al., 2008). Enhanced
MBP staining and regeneration was also observed in the severe
focal spinal EAE model. Together with the reduced inflammatory
CD68+ lesion area, this translated into accelerated functional
recovery.CellBased on the work by Kerschensteiner et al. (2004b), func-
tional recovery in the spinal targeted EAE model is due to
enhanced sprouting and axonal rearrangement at three different
levels: at the spinal lesion site, at regions above the lesion, and in
the motor cortex. We can confirm at least that two of these
mechanisms are enhanced by 5F9. The local sprouting in the
gray matter of the spinal cord was increased, and the same
has been observed for the anterogradely traced corticospinal
tract. These results are unique and have been achieved by sys-
temic application of the 5F9 antibody that binds to the N-terminal
domain of hRGMa, which contains high-affinity binding domains
for neogenin and BMP-2, -4, and -6. One effect of interfering with
RGMa-neogenin binding is a shift of the receptor, neogenin, to
different membrane domains, therefore most likely influencing
downstream signaling. In contrast, another study showed that
systemic application of an antibody targeting the C-terminal
domain of rRGMa reduced severity of relapses in the PLP-EAE
andMOG-EAEmodel (Muramatsu et al., 2011) but did not induce
locomotor improvement after spinal cord injury, only showing
strong enhancement of functional recovery when given intraspi-
nally via osmotic pumps (Hata et al., 2006; Kyoto et al., 2007;
Muramatsu et al., 2011). Additionally, another neogenin-interac-
tion domain has been described in the C-terminal region (259–
295) of hRGMa (Itokazu et al., 2012). Surprisingly, both the
N- and C-terminal domains of chick RGMa, despite sharing no
sequence homology, have been shown to bind the same fibro-
nectin III domain (3–4) and inhibit neurite outgrowth (Tassew
et al., 2012). The processed N-terminal domain of chick RGMa
binds with the highest affinity to neogenin, and its affinity is
more than 10-fold higher than the affinity of the fl RGMa protein
(Tassew et al., 2012). We confirmed these data showing that the
N-terminal domain of hRGMa exerted inhibitory activity on neu-
rite growth and cell migration. In retinae, inhibition of the N-termi-
nal domain resulted in protection of 80% of nerve fibers,
showing the importance of this domain for neuroprotection.
However, most other experiments do not allow one to judge
well whether a different effect is observed with N- and C-terminal
RGMa; therefore, more experiments in the near future will be
needed to give more insight in the functional difference between
the N and C terminus. The latest results from our group (N.G.T.,
A.P.S., and P.P.M., unpublished data) suggest that the N- and
C-terminal RGMa fragments induce different signaling path-
ways, with both fragments being neutralized by RGMa antago-
nists inducing transfer out of lipid rafts.
The observation that CSF samples of progressive MS patients
contained C- and N-terminal RGMa fragments inhibitory to both
axon growth and regeneration suggests that RGMa may
contribute to regeneration failure and neurodegeneration in
MS. A processed N-terminal fragment, very similar in size to
the high-affinity fragment described by Tassew et al. (Tassew
et al., 2012), was also detected in the patients’ CSF samples.
Interestingly, treatment with TCA induced a decrease in concen-
tration of these three fragments. Whether this is associated with
functional improvement cannot yet be answered, as CSF from
MS patients has been reported to possess other regeneration
inhibitory proteins like NOGO A. Testing of a clinical candidate,
RGMa mAb, in MS patients is in the planning stage and might
be started in 2015. This will provide insight into the contributionReports 10, 1887–1898, March 24, 2015 ª2015 The Authors 1895
of RGMa to regeneration inhibition and neurodegeneration in pa-
tients with MS.
Our results in neurodegeneration or inflammatory animal
models confirm previous data generated in spinal cord injury
models or cerebral stroke models where antibody-mediated
neutralization of RGMa (Hata et al., 2006; Kyoto et al., 2007) or
downregulation of RGMa resulted in significant neuroprotection
and enhanced functional recovery (Tao et al., 2013; Feng et al.,
2012; Jiang et al., 2012; Zhang et al., 2011).
The RGMa receptor neogenin plays an important role in cell
death regulation in the embryonic and adult CNS (Fujita et al.,
2008) mediated by two proteins directly bound to neogenin
and released upon RGMa binding: death-associated protein ki-
nase (DAPK) and LIM domain only 4 (LMO4) (Schaffar et al.,
2008; Goldschneider et al., 2008; Fujita et al., 2008). These
two proteins influence different intracellular pathways: DAPK,
on the one hand, affects cellular survival by activating the
apoptotic pathway, and LMO4, on the other hand, affects the
cytoskeleton and gene expression. These changes in gene
expression and LMO4-induced upregulation of ryanodine re-
ceptor type 2 (RyR2) in central neurons have been observed
and might contribute to synaptic plasticity in the hippocampus
(Qin et al., 2012). Another form of plasticity regulation has
been described in cocaine sensitization, where LMO4 represses
anaplastic lymphoma kinase and directly interacts with estrogen
receptor 2 (Lasek et al., 2011). It is not yet understood in detail
how neogenin and RGMa are involved in these neuroplasticity
mechanisms. However, our data on neuroregeneration in the
optic nerve after injury and inflammation, together with the
sprouting of retinal neurons that have the appearance of ama-
crine-like cells, point toward an important role for RGMa in this
process. Additionally, the presence of RGMa in stroke- or
injury-damaged human brain tissue in the plaque regions of
Alzheimer’s disease patients, in the substantia nigra of Parkin-
son’s disease patients, and in MS patients suggests a crucial
and central role for RGMa as an inhibitor of neuroplasticity.
Increasing neuroplasticity in MS patients by targeting RGMa
may delay transition from the RRMS phase to the secondary
progressive MS phase and may promote functional recovery
or functional reconstitution. The availability of clinical RGMa-
neutralizing drug candidates will therefore enable evaluation of
this hypothesis in MS patients.
EXPERIMENTAL PROCEDURES
All MS patients gave written informed consent. An independent local institu-
tional review board approved the additional protein determinations in CSF in
this noninterventional, observational study. Experimental procedures were
approved by the Animal Welfare Office (Ludwigshafen, Germany) and were
performed in accordancewith the recommendations and policies of the United
States National Institutes of Health Principles of Laboratory Animal Care (1996
edition). Animal housing and experiments were conducted in facilities with full
Association for Assessment and Accreditation of Laboratory Animal Care
accreditation.
A detailed description and additional information for the experiments can be
found in Supplemental Experimental Procedures.
Rat ONC Model
Experiments were carried out in adult male Wistar rats obtained from Charles
River (D) Laboratories (Germany). The ONC was performed always only at the1896 Cell Reports 10, 1887–1898, March 24, 2015 ª2015 The Authorleft eye by minimal anterior surgery as described previously (Monnier et al.,
2011). Briefly, animals were anesthetized by inhalation anesthesia using sevo-
flurane (2%–3%, 0.8–1.0 l/min oxygen flow rate) (Abbott) and fixed on the
operation table. For anterior crush surgery of the rat optic nerve, the 1% lido-
caine solution was used to anesthetize the cornea of the left eye. The optic
nerve was exposed and injured by using a pair of forceps set to provide a fixed
maximum pressure for 10–20 s.
Measurement of Retinal Nerve Fibers in Retina Explants
Animals were deep anesthetized and immediately sacrificed and perfusedwith
4% paraformaldehyde (PFA) solution through the left heart ventricle. The eyes
were dissected and placed in 4% PFA. The preparation of the retina was per-
formed in Hank’s balanced salt solution (magnesium- and calcium-free; Life
Technologies). The eye was fixed at the connective tissue by tweezers, and
a round cut was made in sclera just around the cornea in order to remove
the retina. Immunofluorescent staining was performed according to the proto-
col in the supplementary information.
Quantitative analysis of the protective effect of RGMa antibodies on the
RNFL in the eye was done using Axiovision software, randomly selected im-
ages (n = 12) of each retina were chosen, and the number of nerve fibers deter-
mined for each image. Alternatively, composite images of the retina were
prepared and all fiber bundles converging to the optic nerve head were
counted. For these experiments, five to eight retinas with crushed optic nerves
were used for each group. Data analysis and statistical analysis was per-
formed using GraphPad prism program.
Testing of RGMa Antibodies in a Focal Spinal Experimental
Autoimmune EAE Model
Kerschensteiner et al. (Kerscheinsteiner et al., 2004) developed a focal, local-
ized EAE model in which adult female Lewis rats were first immunized with
MOG. Three weeks after immunization, MOG antibody titers were determined
and animals with a positive immune response were injected with a cytokine
mixture (TNF-a 1,000 ng, IFN-g 150 U) locally at thoracic level 8 (T8). Within
1 week after cytokine injection, the rats developed hindlimb motor defects,
tail paralysis, and gait disturbances reaching an EAE score of 2.5.
Rats developed first symptoms within 1 week after cytokine injection, at
which point the antibody treatment was started. An hIgG (directed against
hIL-18, not cross-reactive with rat IL-18) or a rat p21 isotype control antibody
and several different RGMa antibodies (humanized 5F9, rat 5F9) were used,
and rats were treated once per week via the i.v. route. EAE scoring was
done daily, and scores were documented. Individuals conducting the experi-
ments were blinded for the different treatment groups.
After a period of 27–29 days post cytokine administration, the animals were
sacrificed and spinal cords were dissected, post-fixed, and stained with
appropriate antibodies. Sections were observed using a fluorescent micro-
scope (Axiovert 200M, Carl Zeiss).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.02.048.
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